Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleAre oral cannabinoids safe and effective in refractory neuropathic pain?
Author(s)Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D
Journal, Volume, IssueEuropean Journal of Pain 2004;8:173–177
Major outcome(s)No significant decraese of pain in 7 patients, more than 60% decrease in one patient

Although cannabinoids have anti-hyperalgesic e.ects in animal models of nerve injury, there are currently very few prospective trials of the efficacy of cannabinoids in neuropathic pain in humans. This open label prospective study investigated the safety, tolerability and analgesic benefit of oral delta-9-tetrahydrocannabinol (THC) titrated to a maximal dosage of 25 mg/day in 8 consecutive patients with chronic refractory neuropathic pain. Spontaneous ongoing and paroxysmal pain, allodynia and paresthesias were assessed. The sensory and affective components of pain using the McGill pain questionnaire, quality of life, mood, anxiety and functionality were also evaluated. Seven patients suffered from side effects necessitating premature arrest of the drug in 5 of them. THC (mean dosage: 16.6±6.5 mg/day) did not induce any significant effects on ongoing and paroxysmal pain, allodynia, quality of life, anxiety/depression scores and functional impact of pain. These results do not support an overall benefit of THC in pain and quality of life in patients with refractory neuropathic pain.

Dose(s)up to 25 mg
Duration (days)60
Participants8 patients with refractory neuropathic pain
DesignOpen study
Type of publication
Address of author(s)INSERM E-332, Centre d’Evaluation et de Traitement de la Douleur, H^opital Ambroise Paré, AP-HP, 92100 Boulogne-Billancourt, France
Full text

[Back to Overview]  [IACM Homepage]